Changeflow GovPing Pharma & Drug Safety EP3759090A1 Novel Therapeutic Compounds by Infl...
Routine Rule Added Final

EP3759090A1 Novel Therapeutic Compounds by Inflazome Limited

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3759090A1 for novel therapeutic compounds filed by Inflazome Limited. The patent covers heterocyclic compounds with IPC classifications including C07D derivatives and A61P therapeutic activity (anti-inflammatory/analgesic). Designated states include all EU member states plus associated countries. The publication marks the grant of patent rights for these novel compounds.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

EPO published patent application EP3759090A1, granting Inflazome Limited exclusive rights to novel therapeutic compounds with heterocyclic structures (C07D derivatives). The patent includes claims covering A61P 29/00 (anti-inflammatory and anti-rheumatic products) and A61K 31/4439 (pyridine derivatives).

Pharmaceutical manufacturers and drug developers should note this patent when conducting R&D in anti-inflammatory therapeutics. The designated state coverage across EU member states and associated countries provides broad geographic protection for the patented compounds.

What to do next

  1. Monitor patent portfolio for competitive intelligence
  2. Review compound claims for potential licensing opportunities

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL COMPOUNDS

Publication EP3759090A1 Kind: A1 Apr 08, 2026

Applicants

Inflazome Limited

Inventors

MILLER, David, VAN WILTENBURG, Jimmy, MEISSNER, Johannes Wilhem Georg, VAN HERPT, Jochem Theodoor, LION, Zhou Min, SHANNON, Jonathan, ST-GALLAY, Stephen, COOPER, Matthew

IPC Classifications

C07D 401/12 20060101AFI20190907BHEP C07D 213/71 20060101ALI20190907BHEP C07D 401/04 20060101ALI20190907BHEP C07D 405/12 20060101ALI20190907BHEP C07D 409/12 20060101ALI20190907BHEP C07D 409/14 20060101ALI20190907BHEP C07D 413/12 20060101ALI20190907BHEP C07D 417/12 20060101ALI20190907BHEP C07D 213/56 20060101ALI20190907BHEP C07D 213/64 20060101ALI20190907BHEP A61P 29/00 20060101ALI20190907BHEP A61K 31/4439 20060101ALI20190907BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3759090A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug compound patents Pharmaceutical R&D IP portfolio management
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!